Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study Newswire.ca - Thu Sep 19, 6:00AM CDT

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the...

ONCY : 0.9437 (+1.47%)
ONC.TO : 1.28 (-1.54%)
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September Newswire.ca - Fri Sep 6, 7:00AM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

ONCY : 0.9437 (+1.47%)
ONC.TO : 1.28 (-1.54%)
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates Newswire.ca - Mon Aug 12, 3:37PM CDT

/CNW/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns...

ONCY : 0.9437 (+1.47%)
HALO : 59.89 (-3.88%)
CADL : 7.95 (+2.45%)
MRUS : 50.13 (+1.44%)
RHHBY : 39.6100 (+0.71%)
ONC.TO : 1.28 (-1.54%)
Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes BayStreet.ca - Mon Aug 12, 12:44PM CDT

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – Pancreatic cancer is among the...

ONCY : 0.9437 (+1.47%)
ONC.TO : 1.28 (-1.54%)
RHHBY : 39.6100 (+0.71%)
HALO : 59.89 (-3.88%)
CADL : 7.95 (+2.45%)
MRUS : 50.13 (+1.44%)
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference Newswire.ca - Fri Aug 2, 6:00AM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

ONCY : 0.9437 (+1.47%)
ONC.TO : 1.28 (-1.54%)
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights Newswire.ca - Wed Jul 24, 6:00AM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

ONCY : 0.9437 (+1.47%)
ONC.TO : 1.28 (-1.54%)
Cancer Rates Surge: Key Biotech Stocks Leading the Charge in Oncology Drug Development BayStreet.ca - Thu Jun 27, 1:38PM CDT

USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million new cancer cases. In order to respond to the rising...

ONCY : 0.9437 (+1.47%)
ONC.TO : 1.28 (-1.54%)
GSK : 42.31 (-0.28%)
GH : 25.55 (+1.87%)
EXEL : 27.02 (+0.75%)
GILD : 84.58 (+0.82%)
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program Newswire.ca - Thu Jun 27, 6:00AM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced...

ONCY : 0.9437 (+1.47%)
ONC.TO : 1.28 (-1.54%)
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence Newswire.ca - Mon Jun 24, 6:00AM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced...

ONCY : 0.9437 (+1.47%)
ONC.TO : 1.28 (-1.54%)
Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike Newswire.ca - Thu Jun 20, 4:26PM CDT

/CNW/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer...

ONCY : 0.9437 (+1.47%)
ONC.TO : 1.28 (-1.54%)
MBIO : 0.2500 (-1.54%)
LEGN : 50.73 (+1.64%)
JNJ : 166.03 (-0.07%)
NRIX : 25.58 (+3.40%)

Barchart Exclusives

Should You Follow Insider Buying on This Energy Dividend Stock? Barchart - 16 minutes ago
The article examines whether investors should follow insider buying on a promising energy dividend stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot